FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886363485> ?p ?o ?g. }

• W2886363485 abstract "Prostate cancer patients diagnosed with high Gleason score (≥ 8) and large tumors (≥T2c) are considered high-risk patients and >50% will develop an early biochemical relapse following radical surgery. Presently, there is no curative therapy available for patients once when biochemical relapse occur. Based on encouraging clinical results from 6 relapsed prostate cancer patients treated under hospital exemption with dendritic cell (DC) vaccines we started an adjuvant, first in man, phase I/II study using autologous, monocyte derived DCs targeting autologous tumor antigens from primary tumor, combined with hTERT and survivin. Twenty patients were included in the study. All patients had pathological stage pT2-pT3b and Gleason score 7b-10. Following surgery prostate specific antigen (PSA) was 0,5 μg/L with minimum 4 weeks interval) and two additional patients relapsed after completed 3 years of vaccination. From the last 5 patients given the new type of DCs none have experienced PSA relapse. Seventy-five percent of the patients remain without biochemical relapse with a mean observation time of 47,5 (range 29-82) months. We confirm that the study is feasible and safe. Immune responses in the patients are under investigation. Altogether, our clinical results are promising and the use of adjuvant DC vaccines might become a new approach to prevent biochemical relapse in high-risk prostate cancer patients following radical surgery. Citation Format: Anne Merete Tryggestad, Iris Bigalke, Karol Axcrona, Bjorn Brennhovd, T Kirsti Honnashagen, Lisbeth Skoge, Lena Tjeldhorn, Lene Mowinckel, Stein Saeboe-Larsen, Jens A L Jorgensen, Grete S Andreassen, Gjertrud Skorstad, Dag Josefsen, Ulrika Axcrona, Steinar Aamadal, Wolfgang Lilleby, Svein Dueland, Gunnar Kvalheim. A first in man phase I/II adjuvant dendritic cell vaccine study in high-risk prostate cancer patients following radical surgery reduce the incidence of biochemical relapse [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr CT016." @default.
• W2886363485 created "2018-08-22" @default.
• W2886363485 creator A5003977220 @default.
• W2886363485 creator A5005472481 @default.
• W2886363485 creator A5006284779 @default.
• W2886363485 creator A5022793030 @default.
• W2886363485 creator A5022885201 @default.
• W2886363485 creator A5026295198 @default.
• W2886363485 creator A5029109102 @default.
• W2886363485 creator A5036757731 @default.
• W2886363485 creator A5044514299 @default.
• W2886363485 creator A5048625578 @default.
• W2886363485 creator A5048782559 @default.
• W2886363485 creator A5056318188 @default.
• W2886363485 creator A5059857090 @default.
• W2886363485 creator A5061219593 @default.
• W2886363485 creator A5063176873 @default.
• W2886363485 creator A5067305238 @default.
• W2886363485 creator A5068177755 @default.
• W2886363485 creator A5069132715 @default.
• W2886363485 date "2018-07-01" @default.
• W2886363485 modified "2023-09-27" @default.
• W2886363485 title "Abstract CT016: A first in man phase I/II adjuvant dendritic cell vaccine study in high-risk prostate cancer patients following radical surgery reduce the incidence of biochemical relapse" @default.
• W2886363485 doi "https://doi.org/10.1158/1538-7445.am2018-ct016" @default.
• W2886363485 hasPublicationYear "2018" @default.
• W2886363485 type Work @default.
• W2886363485 sameAs 2886363485 @default.
• W2886363485 citedByCount "0" @default.
• W2886363485 crossrefType "proceedings-article" @default.
• W2886363485 hasAuthorship W2886363485A5003977220 @default.
• W2886363485 hasAuthorship W2886363485A5005472481 @default.
• W2886363485 hasAuthorship W2886363485A5006284779 @default.
• W2886363485 hasAuthorship W2886363485A5022793030 @default.
• W2886363485 hasAuthorship W2886363485A5022885201 @default.
• W2886363485 hasAuthorship W2886363485A5026295198 @default.
• W2886363485 hasAuthorship W2886363485A5029109102 @default.
• W2886363485 hasAuthorship W2886363485A5036757731 @default.
• W2886363485 hasAuthorship W2886363485A5044514299 @default.
• W2886363485 hasAuthorship W2886363485A5048625578 @default.
• W2886363485 hasAuthorship W2886363485A5048782559 @default.
• W2886363485 hasAuthorship W2886363485A5056318188 @default.
• W2886363485 hasAuthorship W2886363485A5059857090 @default.
• W2886363485 hasAuthorship W2886363485A5061219593 @default.
• W2886363485 hasAuthorship W2886363485A5063176873 @default.
• W2886363485 hasAuthorship W2886363485A5067305238 @default.
• W2886363485 hasAuthorship W2886363485A5068177755 @default.
• W2886363485 hasAuthorship W2886363485A5069132715 @default.
• W2886363485 hasConcept C121608353 @default.
• W2886363485 hasConcept C126322002 @default.
• W2886363485 hasConcept C143998085 @default.
• W2886363485 hasConcept C2776235491 @default.
• W2886363485 hasConcept C2777008409 @default.
• W2886363485 hasConcept C2777701055 @default.
• W2886363485 hasConcept C2777863537 @default.
• W2886363485 hasConcept C2779466945 @default.
• W2886363485 hasConcept C2780192828 @default.
• W2886363485 hasConcept C2781406297 @default.
• W2886363485 hasConcept C71924100 @default.
• W2886363485 hasConceptScore W2886363485C121608353 @default.
• W2886363485 hasConceptScore W2886363485C126322002 @default.
• W2886363485 hasConceptScore W2886363485C143998085 @default.
• W2886363485 hasConceptScore W2886363485C2776235491 @default.
• W2886363485 hasConceptScore W2886363485C2777008409 @default.
• W2886363485 hasConceptScore W2886363485C2777701055 @default.
• W2886363485 hasConceptScore W2886363485C2777863537 @default.
• W2886363485 hasConceptScore W2886363485C2779466945 @default.
• W2886363485 hasConceptScore W2886363485C2780192828 @default.
• W2886363485 hasConceptScore W2886363485C2781406297 @default.
• W2886363485 hasConceptScore W2886363485C71924100 @default.
• W2886363485 hasLocation W28863634851 @default.
• W2886363485 hasOpenAccess W2886363485 @default.
• W2886363485 hasPrimaryLocation W28863634851 @default.
• W2886363485 hasRelatedWork W1998677622 @default.
• W2886363485 hasRelatedWork W2018611093 @default.
• W2886363485 hasRelatedWork W2035761559 @default.
• W2886363485 hasRelatedWork W2038120654 @default.
• W2886363485 hasRelatedWork W2133649938 @default.
• W2886363485 hasRelatedWork W2160696511 @default.
• W2886363485 hasRelatedWork W2228153896 @default.
• W2886363485 hasRelatedWork W2408089991 @default.
• W2886363485 hasRelatedWork W2581930322 @default.
• W2886363485 hasRelatedWork W3093796690 @default.
• W2886363485 isParatext "false" @default.
• W2886363485 isRetracted "false" @default.
• W2886363485 magId "2886363485" @default.
• W2886363485 workType "article" @default.